When Dr Homer Stryker, an orthopaedic surgeon from Kalamazoo, Michigan, U.S., found that certain medical products were not meeting his patients’ needs, he invented new ones. As interest in these products grew, Dr Stryker started a company in 1941 to produce them.
Today, we are one of the world's leading medical technology companies, and alongside our customers, we are impacting the lives of millions of patients each year. Our diverse array of innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine help improve patient and healthcare outcomes. As our portfolio grows, our culture still reflects Dr Stryker’s legacy, and we are well-positioned to continue making healthcare better for generations to come.
Innovation is in our DNA
Learn more about Dr Homer Stryker, and the legacy that inspires our mission.
Dr Homer Stryker, the Company’s founder, invents the turning frame and walking heel while completing a degree in orthopaedic surgery at the University of Michigan.
Dr Stryker begins his medical practice in Kalamazoo, Michigan, and establishes offices in Borgess Hospital. He uses the basement area for research and development.
Dr Stryker creates The Orthopaedic Frame Company.
Manufacturing of the Wedge Turning Frame begins, which allowed carers to turn patients with serious back injuries, while keeping the spine immobilised.
Dr Stryker incorporates The Orthopaedic Frame Company.
We patent the oscillating saw; it cuts hard cast material but not human tissue. This product is the forerunner to a broad line of our surgical instruments.
Dr Stryker’s son, Lee, becomes the General Manager of the Company.
A decade in development, the Circ-O-Lectric bed capitalises on the legacy of the turning frame.
Our sales reach US$1 million.
Dr Stryker retires from his medical practice, and we change our name to Stryker Corporation.
The 1960s usher in a new era of product development with the micro reciprocating saw.
Lee Stryker becomes our President.
The Company’s sales grow to US$17.3 million.
Lee Stryker dies in a plane crash.
We name John Brown President and Chief Executive Officer of Stryker Corporation.
The initial public offering of stock brings greater awareness of the Company.
Stryker acquires Osteonics Corp. and enters the orthopaedic implant market.
Dr Stryker dies aged 85 and John Brown becomes Stryker’s Chairman.
Divisionalisation brings focus to each of our three major product groups.
The purchase of SynOptics provides expansion into the endoscopy business.
Our annual sales reach US$100 million.
The acquisition of Dimso, SA opens opportunities in the spinal fixation field.
We introduce RUGGED™ ambulance cots to expand into emergency medical services.
The acquisition of Osteo SA provides entry into the orthopaedic trauma market.
We are listed on the New York Stock Exchange after 18 years on NASDAQ.
We acquire Howmedica, a major player in the worldwide orthopaedic market, and double in size in the following year.
We enter the surgical navigation market, providing precision in locating surgical targets.
The Dekompressor and PCD System provide entry into the interventional spine market.
We are listed on the FORTUNE 500 for the first time.
Stephen MacMillan becomes President and Chief Executive Officer and John Brown transitions to the role of Chairman of the Board.
We acquire Ascent Healthcare Solutions, Inc., the market leader in the reprocessing and remanufacturing of medical devices in the US.
John Brown retires as Chairman and Stephen MacMillan becomes Stryker’s third Chairman of the Board.
Our sales grow to US$7.3 billion.
We are listed in FORTUNE magazine’s 100 Best Companies to Work For for the first time.
We acquire Boston Scientific’s Neurovascular division, greatly expanding our neurotechnology business.
Kevin Lobo becomes President and Chief Executive Officer.
We acquire Trauson Holdings Company Limited and expand into the value segment of the emerging markets.
The acquisition of MAKO Surgical Corp. provides opportunities to further advance the growth of robotic arm assisted surgery in orthopaedics.
Kevin Lobo becomes Chairman of the Board and our fourth Chairman.
Closed five acquisitions:
• Pivot Medical, Inc
• Patient Safety Technologies, Inc.
• CoAlign Innovations, Inc.
• Berchtold Holding AG
• Small Bone Innovations, Inc.
Our sales exceed US$10 billion for the first time, and we complete eight acquisitions, including two in our Medical division:
• Sage Products, LLC,
• Physio-Control International, Inc.
We launch Mako Total Knee, which combines our Mako Robotic-Arm Assisted Technology with the Triathlon Total Knee System.
Fortune and Great Place to Work named us one of the World’s Best Workplaces for the first time.
The acquisition of NOVADAQ expands our expertise in fluorescence imaging technology.
Two new members join our Board of Directors, making it one of the most diverse among Fortune 500 companies.
Timothy Scannell is appointed President and Chief Operating Officer.
We acquire K2M Group Holdings, which reinforces our spine offering in the complex and minimally invasive segments.
Celebrating 40 years as a publicly-traded company, our leadership rings the New York Stock Exchange (NYSE) closing bell.